Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit (Journal article)

Dova, L./ Pentheroudakis, G./ Golfinopoulos, V./ Malamou-Mitsi, V./ Georgiou, I./ Vartholomatos, G./ Ntemou, A./ Fountzilas, G./ Pavlidis, N.


AIMS: In view of available targeted therapies, we investigated the presence of c-kit, PDGFR gene mutations and protein expression in cancer of unknown primary (CUP) in order to study their contribution in pathogenesis, their prognostic value and potential as therapeutic targets. METHODS: Mutations in hot spots c-kit exon 11 and PDGFR exons 12 and 18 were studied in paraffin-embedded tumour samples from 50 patients with CUP by means of PCR-based single-strand conformational polymorphism and protein expression by means of streptavidin-biotin immunoperoxidase assays. Molecular markers were screened for possible correlations with patient outcome. RESULTS: No shifted band was detected in any of the polyacrylamide gel electrophoreses, indicating absence of c-kit exon 11 and PDGFR exon 12, 18 mutations. Immunohistochemical analysis in 37 tumours revealed positive membranous CD117 expression in 30 samples (81%) of which five exhibited strong (+3), four moderate (+2) and 21 weak (+1) staining. PDGFRa protein staining was seen in 15 out of 30 (50%) cases, mostly weak (13) and rarely moderate (1) or strong (1). The expression of KIT or PDGFRa protein did not correlate with the clinical outcome of the patients in our cohort. CONCLUSIONS: In a moderate-sized CUP patient cohort, KIT or PDGFRa protein overexpression is rare, does not have gross prognostic significance for survival and is not associated with presence of activating mutations.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Aged,Aged, 80 and over,Exons,Female,Gastrointestinal Stromal Tumors/drug therapy/genetics,Humans,Immunohistochemistry,Indoles/therapeutic use,Male,Middle Aged,Mutation,Neoplasms, Unknown Primary/*drug therapy/genetics/mortality,Piperazines/therapeutic use,Polymorphism, Genetic,Prognosis,Proto-Oncogene Proteins c-kit/analysis/*genetics,Pyrimidines/therapeutic use,Pyrroles/therapeutic use,Receptors, Platelet-Derived Growth Factor/analysis/antagonists &,inhibitors/*genetics
URI: http://olympias.lib.uoi.gr/jspui/handle/123456789/24718
ISSN: 0171-5216
Link: http://www.ncbi.nlm.nih.gov/pubmed/18064489
http://www.springerlink.com/content/37nkj143gq35w162/fulltext.pdf
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Dova-2008-Targeting c-KIT, PDG.pdf428.76 kBAdobe PDFView/Open    Request a copy



 Please use this identifier to cite or link to this item:
http://olympias.lib.uoi.gr/jspui/handle/123456789/24718
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.